Pharmaceutical Executive-10-01-2022

Click the title above for a link to open the 2022 Pharmaceutical Executive APEX Awards Program in an interactive PDF format.

Reaching new heights in sustainability a win-win for industry.

Pharma supply chains are no longer hidden beyond the reach of ESG agendas, making it important for companies to accelerate adoption of new manufacturing processes and environmental technology.

Big pharma’s finicky appetite for M&A comes as valuations of sellers soften. Though the pace of deals has picked up some, predicting just how long both sides will hold tight remains difficult.

Bristol Myers Squibb commercial head Chris Boerner believes a straightforward formula is the best formula in advancing innovation and developing talent in today’s complex healthcare climate—an approach he roots in authenticity and “not over engineering,” whether tackling business or culture.

As fundamentals improve, potential rate plateau could ignite growth.

Different paths to formulary decision-making.

Three simple ways to build trust—by reaching outside your comfort zone.

Global go-to-market strategies in region require a revamped gameplan.

Patient safety and data protection concerns highlight hesitancy.

FDA backs joint reviews and common research policies around world.

Top hubs continue to perform despite financial uncertainty in other industries.

Click the title above for a link to open the Pharmaceutical Executive October 2022 issue in an interactive PDF format.

How pharma companies can make sure their corporate strategy in ESG is appealing to younger generations—and aligns with the issues this large segment of sustainability investors care about most.